Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Osteoporosis, Postmenopausal Clear all

Conditions: Osteoporosis, Multiple Myeloma
Interventions: Romosozumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Osteoporosis
Interventions: zoledronic acid; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Up to 85 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Osteopenia, Osteoporosis
Interventions: Alendronate, Estrogen/progestin therapy; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 60 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Osteoporosis, Postmenopausal
Interventions: Risedronate, Raloxifene, Placebo; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: Up to 65 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Post Menopausal Osteoporosis
Interventions: Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more

Conditions: Osteoporosis, Postmenopausal
Interventions: teriparatide, raloxifene HCl, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Maywood, Illinois • Portland, Oregon

Conditions: Osteoporosis, Postmenopausal
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 50 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Osteoporosis
Interventions: placebo, risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 57 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Tuscon, Arizona • Omaha, Nebraska • Cincinnati, Ohio

Conditions: Osteoporosis
Interventions: Parathyroid hormone related protein(1-36), Parathyroid hormone (1-34); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoporosis
Interventions: Apomine; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 2
States / cities: Omaha, Nebraska • West Haverstraw, New York

Conditions: Osteoporosis, Osteopenia
Interventions: Virtual Bone Biopsy, Teriparatide, Zoledronic Acid; Other · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 60 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postmenopausal Osteoporosis
Interventions: Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Gainesville, Georgia • Bethesda, Maryland

Conditions: Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions: denosumab, Placebo, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Susan L. Greenspan; Other
Eligibility: 65 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoporosis
Interventions: PTH/Calcium, PTH/placebo, placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 17
States / cities: Rancho Cucamonga, California • Lake Worth, Florida • Coeur d'Alene, Idaho + 14 more

Conditions: Postmenopausal Osteoporosis, Osteoporosis
Interventions: synthetic hPTH 1-34; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 46 Years to 85 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Postmenopausal
Interventions: teriparatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Tucson, Arizona • Lakewood, Colorado • Omaha, Nebraska + 2 more

Conditions: Post Menopausal Osteoporosis
Interventions: Ibandronate [Bonviva/Boniva], Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 1,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 20
States / cities: Irvine, California • Loma Linda, California • Los Angeles, California + 17 more

Conditions: Postmenopausal Osteoporosis
Interventions: Denosumab (CP2), Denosumab (CP4); Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 100 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Santa Maria, California • South Lake Tahoe, California • Lakewood, Colorado + 7 more

Conditions: Osteoporosis
Interventions: Not listed
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Postmenopausal Osteoporosis
Interventions: Not listed
Lead sponsor: Warner Chilcott; Industry
Eligibility: Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more

Conditions: Osteoporosis
Interventions: SB-751689; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Postmenopausal Osteoporosis
Interventions: Ibandronate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Female only
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 60
States / cities: Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more

Conditions: Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions: Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Osteoporosis
Interventions: Placebo, Soy isoflavones; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 403 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 3
States / cities: Davis, California • Athens, Georgia • Houston, Texas

Search by objective public record fields.

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid

Bone Microarchitecture in Osteopenic Postmenopausal Women

Comparison Study of PTHrP and PTH to Treat Osteoporosis

An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass

µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Preventing Osteoporosis Using Denosumab

Calcium Supplementation in Postmenopausal Women

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Role of T-cells in Post-Menopausal Osteoporosis

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

Effect of Blueberries on Bone Turnover

Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss